FDA-Approved Anti-Amyloid Medications
- Lecanemab was approved in July 2023 and has been available at Cleveland Clinic since then.
- Donanemab was approved in July 2024, with distribution expected to begin later in 2024.
Both therapies are monoclonal antibodies designed to slow the progression of Alzheimer’s disease in its early stages by targeting amyloid beta plaques in the brain.
Patient Eligibility and Usage
- Who is eligible?
Patients with mild Alzheimer’s symptoms and confirmed amyloid beta plaques in their brain may be prescribed these therapies.
- Who is not eligible?
These treatments are not for patients in moderate to late stages of Alzheimer’s or those with other forms of cognitive impairment, like vascular dementia or Lewy body dementia.
Treatment Details
- How they work:
Both therapies are infused directly into a vein. Lecanemab is administered biweekly, while donanemab is given monthly.
- Monitoring and safety:
Common side effects include brain swelling and bleeding, monitored via regular MRI scans.
- Concomitant medications:
Patients can continue symptom-modifying Alzheimer’s drugs (e.g., donepezil, rivastigmine) while undergoing anti-amyloid therapy.
Access and Insurance
- Cleveland Clinic Lou Ruvo Center for Brain Health has been administering lecanemab since 2023. Donanemab’s availability is expected later in 2024, pending Medicare requirements.
- Insurance coverage is available for lecanemab, and similar coverage is anticipated for donanemab.
Evaluation for Therapy
- Current patients:
Discuss anti-amyloid therapy options during your next scheduled appointment or send questions via MyChart.
- New patients:
Request a referral to the Lou Ruvo Center for Brain Health to be evaluated for eligibility.
Additional Research
The Lou Ruvo Center continues to conduct clinical trials for Alzheimer’s treatments. Interested individuals can learn more at Cleveland Clinic’s clinical trials page or contact the Nevada team directly at 702.701.7944 or [email protected].
This resource underscores the importance of discussing risks, benefits, and eligibility criteria with a qualified provider before beginning treatment.
Donate Now